MLYS
Mineralys Therapeutics, Inc.
NASDAQ · Healthcare · Biotechnology · US
$20.92
+3.05%Price chart
Sep 18Sep 23Sep 28Oct 1Oct 6Oct 9Oct 14Oct 19
Key dataOct 19, 2026
Open$20.57
From 52W high−55.80%
Volume1.12M
Market cap$1.85B
P/E (TTM)—
P/S (TTM)—
Div yield—
Key dataOct 19, 2026
Open
$20.57
From 52W high
−55.80%
Volume
1.12M
Market cap
$1.85B
ValuationView details →
P/E (Fwd)
—
EV/EBITDA
−3.7x
P/E (TTM)
—
RSI (14)
34.6
MomentumView details →
1D Return
+3.05%
YTD Return
−42.86%
SummaryUpdated Jun 1, 2026
Mineralys Therapeutics, Inc. (NASDAQ:MLYS) is a clinical-stage biopharmaceutical company founded in 2019 and headquartered in Radnor, Pennsylvania. The company went public in February 2023 and focuses on developing innovative therapies for hypertension and associated cardiovascular diseases. Mineralys is currently advancing its lead drug candidate, lorundrostat, through multiple Phase III clinical trials targeting patients with uncontrolled and resistant hypertension, representing a significant unmet medical need affecting millions of patients worldwide.
Similar companies
Latest newsMore news →
Mineralys Therapeutics, Inc. presented new analyses from the pivotal Mineralys Therapeutics, Inc. showing that 46% of participants with difficult-to-treat hypertension receiving lorundrostat 50 mg achieved the AHA/ACC Guideline systolic blood pressure target.10d agoMineralys Therapeutics announced that new data from the Launch-HTN trial of lorundrostat will be presented at the American Society of Nephrology Kidney Week 2026, held October 21-25 in Denver, Colorado.17d agoMineralys Therapeutics announced that five abstracts on its lorundrostat data will be presented at the American Heart Association Hypertension Scientific Sessions 2026 in Arlington, Virginia, on October 7-11.18d ago